- 2021
-
Press releases - 17.03.2021
COVIREIVAC Platform: COVID-19 Vaccine Research Continues with the Launch of New Projects
Launched in October last year, the purpose of the COVIREIVAC platform coordinated by Inserm and F-CRIN in conjunction with 32 university hospitals and a network of 11 immunology laboratories is to conduct and promote first-class clinical vaccination research in France.
-
Press releases - 15.03.2021
Certains cocktails de pesticides favoriseraient le risque de cancer du sein chez les femmes ménopausées
Certains pesticides utilisés en Europe sont suspectés d’avoir des effets néfastes sur la santé humaine. Ils provoqueraient des perturbations hormonales et auraient également des propriétés carcinogènes, déjà observées en milieu professionnel. Le lien entre l’exposition à ces pesticides via l’alimentation et le cancer du sein dans la population générale est encore peu étudié.
-
Press releases - 09.03.2021
Charcot-Marie Tooth disease: A 100% French RNA-based therapeutic innovation
Charcot-Marie Tooth disease is the most common hereditary neurological disease in the world. It affects the peripheral nerves and causes progressive paralysis of the legs and hands. No treatment is currently available to fight this disease, which is due to the overexpression of a specific protein.
-
Press releases - 04.03.2021
COVID-19: Timing Issues Prevent SARS-CoV-2 Host Cells From Stopping Replication
Les cellules cibles du SARS-CoV-2 dans les voies respiratoires produisent des molécules antivirales suite à l’infection, mais trop tardivement pour empêcher la réplication du virus.
-
Press releases - 25.02.2021
A Toxin Causing DNA Damage Found in Patients with Urinary Tract Infections
Urinary tract infections affect over 50% of women, in some cases recurrently. E. coli bacteria are very often implicated in their development.
-
Press releases - 23.02.2021
A Major Breakthrough in Understanding the Predisposition of Newborns to Group B Streptococcal Meningitis
Every year throughout the world, Group B Streptococcal (GBS) meningitis affects thousands of newborns. Often fatal, the disease can also lead to severe after-effects in survivors.
-
Press releases - 19.02.2021
Improving immunotherapies for blood cancers: real-time exploration in the tumor
Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.” But how do these antibodies function within the tumor? And how can we hope to improve their efficacy?
-
Press releases - 18.02.2021
Communiquer pendant nos rêves, c’est possible !
Lorsque nous rêvons, nous sommes à première vue coupés du monde, incapables de recevoir des informations de l’environnement et d’y répondre. Pour la première fois, une collaboration entre des chercheurs de l’Inserm, de l’AP-HP, de Sorbonne Université et du CNRS avec plusieurs groupes américains, allemands et néerlandais, montre qu’une communication à double-sens, de l’expérimentateur vers le rêveur et vice-versa est possible au cours du rêve.
-
Press releases - 10.02.2021
Was SARS-CoV-2 Already in France in November 2019?
Based on a retrospective analysis of serum samples from over 9,000 adults participating in the French cohort Constances[1], a study by Inserm researchers found that out of the 353 participants with positive SARS-CoV-2 antibody tests, 13 had had their samples taken between November 2019 and January 2020 – with confirmation by neutralizing antibodies testing. Investigations in 11 of these participants revealed the existence of symptoms possibly related to a SARS-CoV-2 infection or situations at risk of potential SARS-CoV-2 exposure.
-
Press releases - 05.02.2021
Maturation et persistance de la réponse lymphocytaire B mémoire anti-SARS-CoV-2
Une étude sur la mémoire immunitaire montre la maturation et la persistance de la mémoire immunitaire B contre le virus SARS-CoV-2 au cours du temps.